Novavax, Inc. (NVAX)
The company now
Novavax, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Gaithersburg, MD. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $1.1 billion and a profit of $440 million (its filed statements).
From its filings and filed figures; the desk's account of it is not written yet.
Where the revenue comes from
fiscal 2025, as filedRevenue by product, fiscal 2025
| Product | Fiscal 2025 | Fiscal 2024 | Share of revenue |
|---|---|---|---|
| Nuvaxovid Sales | $625M | $190M | 55.6% |
| Licensing Royalties and Other | $438M | $469M | 39.0% |
| Supply Sales | $59.9M | $23.0M | 5.3% |
As tagged in its annual report (Form 10-K, filed Feb 26, 2026 ↗), read from the SEC's financial statement data sets. The year before is the figure the record holds for the prior fiscal year.
The desk's written account of this company, its Past, Present and Future, is not on file yet.
How the company works
The desk has not read this company's annual report yet.
The record in brief
The desk has not written this company's report yet.